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Abstract
We have previously demonstrated that modulating molecular chaperones with KU-32, a 
novobiocin derivative, ameliorates physiologic and bioenergetic deficits of diabetic peripheral 
neuropathy (DPN). Replacing the coumarin core of KU-32 with a meta-fluorinated biphenyl ring 
system created KU-596, a novobiocin analogue (novologue) that showed neuroprotective activity 
in a cell-based assay. The current study sought to determine whether KU-596 offers similar 
therapeutic potential for treating DPN. Administration of 2–20 mg/kg of KU-596 improved 
diabetes induced hypoalgesia and sensory neuron bioenergetic deficits in a dose-dependent 
manner. However, the drug could not improve these neuropathic deficits in diabetic heat shock 
protein 70 knockout (Hsp70 KO) mice. To gain further insight into the mechanisms by which 
KU-596 improved DPN, we performed transcriptomic analysis of sensory neuron RNA obtained 
from diabetic wild-type and Hsp70 KO mice using RNA sequencing. Bioinformatic analysis of the 
differentially expressed genes indicated that diabetes strongly increased inflammatory pathways 
and that KU-596 therapy effectively reversed these increases independent of Hsp70. In contrast, 
the effects of KU-596 on decreasing the expression of genes regulating the production of reactive 
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oxygen species were more Hsp70-dependent. These data indicate that modulation of molecular 
chaperones by novologue therapy offers an effective approach toward correcting nerve 
dysfunction in DPN but that normalization of inflammatory pathways alone by novologue therapy 
seems to be insufficient to reverse sensory deficits associated with insensate DPN.
Keywords
Bioenergetics; diabetic neuropathy; inflammation; molecular chaperones; oxidative stress; RNA 
Seq
Diabetes is a major public health concern in the United States and worldwide. The number 
of diabetic patients is estimated to exceed 500 million by 2030,1 and greater than half of 
these individuals are likely to develop diabetic peripheral neuropathy (DPN), the most 
common diabetic complication. Patients with both type 1 and type 2 diabetes can develop 
either a painful or an insensate peripheral neuropathy that greatly reduces quality of life. 
Unfortunately, despite our increased understanding of the etiology of DPN, few FDA-
approved treatments exist for managing painful DPN, and no approved treatments are 
available to ameliorate insensate DPN. Currently, the most effective approach for decreasing 
the risk of developing or ameliorating DPN is tight glycemic control. However, prolonged 
tight glycemic control is difficult to obtain for the average patient and is more effective in 
type 1 versus type 2 diabetics.2,3
The onset of insensate DPN is associated with numerous pathophysiological changes that 
involve increased flux of glucose through the polyol pathway, enhanced protein 
modification by N-acetylglucosamine, production of advanced glycation end products 
(AGEs), increased oxidative and nitrosative stress, protein kinase C activation, altered 
growth factor signaling, and changes in mitochondrial bioenergetics (mtBE). Many excellent 
reviews have characterized the progress in elucidating mechanisms that contribute to the 
development of DPN and the outcomes of pharmacologic efforts to improve disease 
management.4–9 Though targeting many of these pathways has effectively reversed 
insensate DPN in animal models, translational success in humans has not materialized at this 
point. Given the complex natural history of the disease, which can develop over decades, 
and the uncertainty of the necessity of any one pathogenic component to disease progression 
at a given stage, a polypharmacy approach may prove useful. On the other hand, it is 
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increasingly appreciated that effective management of complex, chronic neurodegenerative 
diseases such as Alzheimer’s disease and DPN may not necessarily require targeting a 
pathway or protein considered to contribute to disease progression. Alternatively, it may 
prove sufficiently beneficial to pharmacologically enhance the activity of endogenous 
neuroprotective pathways to aid neuronal recovery and to tolerate diabetic stress.10
Molecular chaperones such as heat shock protein 90 (Hsp90) and Hsp70 are essential for the 
folding or refolding of newly translated or denatured proteins. Though distinct genes, Hsp90 
and Hsp70 are intimately related via the heat shock response. Hsp90 binds the transcription 
factor heat shock factor 1 and inhibits its transactivating capacity. Upon exposure to stress or 
classic N-terminal Hsp90 inhibitors, heat shock factor 1 dissociates, translocates to the 
nucleus, and upregulates antioxidant genes and a variety of chaperones, including Hsp70.11 
Stimulating this aspect of Hsp90 biology can have potential utility for treating 
neurodegenerative diseases associated with protein misfolding since an increase in Hsp70 
can decrease protein aggregation in Alzheimer’s12,13 and other neurodegenerative 
diseases.14–16 Hsp90 inhibitors have also been developed that bind within the ATP-binding 
domain in the protein’s C-terminus, and we have focused on developing this class of 
inhibitors in treating DPN. Pharmacological modulation of Hsp90 with KU-32 (Figure 1A), 
a first-generation novobiocin-based, C-terminal binding drug, decreased glucose-induced 
death of primary sensory neurons and improved electrophysiologic, psychosensory, 
bioenergetic, and morphologic deficits of DPN in a Hsp70-dependent manner.17–19
Though KU-32 is quite efficacious in treating DPN, molecular modeling of the drug docked 
to the Hsp90 C-terminal binding pocket indicated that the coumarin lactone appeared too 
distant from Lys539 to provide complementary interactions with this residue. Additionally, 
the 3-amido side chain of KU-32 projected into a large hydrophobic pocket that could 
accommodate more flexible linkers.20 Consequently, novologues (novobiocin analogues) 
were designed to contain a biphenyl scaffold that replaced the coumarin lactone of KU-32. It 
was hypothesized that the B-ring of the biphenyl would project into the Hsp90 C-terminal 
binding pocket and serve as a lead compound for further diversification. Subsequent 
modifications supported that substitution of electronegative atoms in the meta-position of 
the benzene ring had improved neuroprotective activity, potentially due to an enhanced 
interaction with Lys539 in the Hsp90 C-terminal binding pocket.20 KU-596 (Figure 1B) was 
identified as a meta-3-fluorophenyl substituted novologue that exhibited an improved ED50 
for protecting primary sensory neurons against glucotoxicity compared with KU-32.
Since KU-32 therapy was associated with a Hsp70-dependent restoration of mitochondrial 
respiratory capacity and reduced oxidative stress in sensory neurons,19,21 we sought to 
determine whether KU-596 displays similar Hsp70-dependent efficacy in animal models of 
DPN. Further, since Hsp70 has numerous cytoprotective properties,22 we hypothesized that 
multiple genes or gene networks within sensory neurons may contribute to the reversal of 
insensate DPN by KU-596 in an Hsp70-dependent manner.
The application of system biology approaches has yielded novel insight into metabolomic 
and genetic networks that contribute to the development of DPN in animal models of type 2 
diabetes23,24 and that distinguish humans with progressive versus nonprogressive DPN.25 
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Though the use of microarrays has successfully defined diabetes-induced changes in the 
peripheral nerve transcriptome, DNA microarrays have a small dynamic range and lack 
sensitivity for quantifying genes expressed either at low or very high levels due to 
background array signals or signal saturation.26 In contrast, high throughput transcript 
sequencing (RNA-Seq) has a dynamic range spanning 5 orders of magnitude and permits 
detection of abundant and even very rare transcripts, with sufficient sequencing depth.27 
Following sequencing, the resulting reads are aligned to a reference genome and qualitative 
or quantitative results are obtained through bioinformatic analysis of the sequencing data.26 
Therefore, we examined transcriptomic changes within sensory neurons that contribute to 
the reversal of insensate DPN using the RNA-Seq approach. Collectively, these data provide 
novel insight into the role of mitochondrial dysfunction, oxidative stress, and inflammation 
in the onset and attenuation of insensate DPN and further corroborate the therapeutic 
potential of modulating molecular chaperones as a treatment for DPN.
RESULTS AND DISCUSSION
KU-596 Dose-Dependently Improves Sensory Function and Mitochondrial Bioenergetics in 
Diabetic Mice
After 14 weeks of diabetes, Swiss Webster mice displayed significantly elevated fasting 
blood glucose (FBG) and glycated hemoglobin (HbA1c) levels, a measure of blood glucose 
control over a 2–3 month period (Table 1). Diabetes also promoted a significant decrease in 
body weight. KU-596 treatment did not improve FBG, HbA1c, or body weight in the 
diabetic mice, as reported previously with KU-32. By 8 weeks of diabetes, the mice 
developed significant mechanical (Figure 2A) and thermal (Figure 2B) hypoalgesia. After 8 
weeks of diabetes, KU-596 was administered for 6 weeks via a once per week 
intraperitoneal dosing at 2, 10, or 20 mg/kg. These treatments dose-dependently reversed the 
pre-existing psychosensory deficits. KU-596 also dose-dependently prevented the diabetes-
induced deficits in motor (MNCV) and sensory (SNCV) nerve conduction velocities (Figure 
2C). Since these electrophysiologic measures were not assessed prior to drug treatment, we 
cannot necessarily conclude that the novologue reversed any pre-existing electrophysiologic 
deficits, as reported with KU-32.28
To determine whether the changes in psychosensory function and NCV were accompanied 
by improvements in mtBE, sensory neurons were isolated from the L4–L6 lumbar ganglia 
after 14 weeks of diabetes; these neurons provide the axons that are affected in DPN and 
were improved by novologue treatment. The diabetic sensory neurons showed a significant 
decline in maximal respiratory capacity (MRC) in response to the protonophore FCCP. This 
response indicates an impaired rate of maximal respiration in the absence of the constraints 
imposed by the proton gradient across the inner mitochondrial membrane (Figure 3A).
Similarly, diabetes decreased spare respiratory capacity (SRC) (Figure 3B), which is an 
assessment of the bioenergetic reserve that is available to respond to cellular energy 
demands. Both of these bioenergetic parameters were dose-dependently improved by 6 
weeks of KU-596 treatment. The ability of KU-596 to increase MRC and SRC in the 
diabetic mice suggests that modulating molecular chaperones is improving the efficiency of 
electron transport. A few possibilities underlying this effect may be due to drug treatment 
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rectifying some damaging effects of prolonged hyperglycemia on proteins involved in 
electron transport or via improving the generation of reducing equivalents or substrate 
availability to the diabetic mitochondria. Thus, similar to KU-32,21 the improvement in 
sensory function correlates with an increase in the bioenergetic capacity of the sensory 
neurons by KU-596. Of interest, the novologue also increased mitochondrial function in 
nondiabetic mice but had no effect on the sensory measures. Thus, this increase in 
mitochondrial function is not sufficient to alter nerve sensory physiology in nondiabetic 
mice.
KU-596 Improves Sensory Parameters in a Hsp70-Dependent Manner
In our previous studies, the neuro-protective efficacy of KU-32 in reversing the sensory and 
respiratory deficits required the presence of Hsp70 since neuropathic Hsp70 KO mice were 
insensitive to drug treatment.21 To determine whether the efficacy of KU-596 also required 
stress-inducible Hsp70, C57Bl/6 and Hsp70 KO mice were rendered diabetic and after 12 
weeks of diabetes, the mice were administered 20 mg/kg KU-596 weekly via oral gavage for 
4 weeks. Both genotypes developed extensive diabetes as shown by a loss of body weight 
and increase in FBG and HbA1c levels (Table 2). Similar to the Swiss Webster mice, none 
of these parameters were affected by novologue therapy. By 12 weeks of diabetes, wild-type 
(WT) and Hsp70 KO diabetic mice showed significant decreases in their response to 
mechanical (Figure 4A,B) or thermal (Figure 4C,D) stimuli indicating that Hsp70 is not 
necessary to develop insensate DPN. Four weeks of KU-596 treatment significantly reversed 
the sensory hypoalgesia in WT mice (Figure 4A,C) but not the Hsp70 KO mice (Figure 
4B,D). Thus, the above results suggest that the novologue also reverses sensory deficits of 
DPN in a Hsp70-dependent manner.
RNA-Seq Analysis of Sensory Neurons
To determine the transcriptome changes within sensory neurons that may contribute to the 
more complete recovery of function that occurs with 6–8 weeks of treatment with KU-596, 
the mice were only treated for 4 weeks. To this end, NCV or sensory neuron bioenergetics 
were not assessed in these animals to avoid any potential changes in transcript expression 
for subsequent RNA-Seq analysis. RNA was isolated from the L4–L6 lumbar DRG of two 
mice per treatment with three to five biologic replicates per group for RNA-Seq analysis. In 
the WT mice, 23 112 genes were detected by RNA-Seq and 39.6% were expressed too low 
or were not detected in all the treatments, yielding 13 959 genes that were statistically 
analyzed. Of these genes, 343 were significantly modified in diabetic WT compared with 
control neurons, with the majority showing an increase in expression. KU-596 treatment 
significantly altered the expression of 174 genes in diabetic sensory neurons and 42 genes in 
control sensory neurons. Among the subset of transcripts that were significantly altered by 
diabetes in the absence or presence of KU-596, 67/70 had their expression decreased by the 
drug in the diabetic neurons. Impressively, KU-596 consistently decreased transcript 
expression in an almost quantitatively opposite direction (Figure 5A). Surprisingly, only 101 
were genes were significantly modified in sensory neurons from the diabetic Hsp70 KO 
mice. Moreover, KU-596 treatment significantly altered 242 genes in these mice despite 
having no effect on improving the sensory measures; the drug altered 37 genes in control 
sensory neurons from the Hsp70 KO mice. Among the shared genes, 31 were increased in 
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diabetic Hsp70 KO neurons and decreased by KU-596 treatment (Figure 5B). Interestingly, 
the magnitude of the normalization in gene expression was similar to the efficacy of KU-596 
in diabetic WT mice. Thus, the drug does not require Hsp70 to correct the expression of all 
genes, and only 8 genes were similarly affected by KU-596 in both WT and Hsp70 KO mice 
(red in Figure 5). Supporting Tables 1 and 2, Supporting Information, provide the CuffDiff 
output (see Methods) for all treatments in WT and Hsp70 KO mice, respectively. The tables 
can be filtered to readily indicate the genes that showed a significant differential expression 
(q ≤ 0.05).
To validate the RNA-Seq analysis, several genes that were altered in both the untreated 
diabetic and STZ + KU-596 treated WT mice were chosen for qRT-PCR analysis in 
independent samples. Due to limits in the amounts of RNA obtained from each DRG 
sample, seven genes with an FPKM ≥ 5 (see Methods) were selected for qRT-PCR analysis 
(arhgdib, fabp4, fkbp5, lcn2, ltf, s100a8, txnip). Though only txnip and fkbp5 showed 
statistical significance due to the variability in the small sample size (n = 3 in each group), 
the other selected genes followed similar trends in the qRT-PCR analysis compared with the 
RNA-Seq data (Figure 6). Collectively, these data suggest that KU-596 can reverse 
transcriptome alterations in the sensory neurons of type 1 diabetic mice.
Novologue Therapy Improves Markers of Inflammation
To gain insight into biological processes that were altered by diabetes and normalized by 
novologue therapy, pathway analysis of the differentially expressed transcripts revealed that 
inflammation was a top biologic process induced by diabetes (Figure 7A). The change in 
gene expression in the untreated diabetic group relative to nondiabetic mice was predicted to 
upregulate inflammatory responses, which supports the involvement of inflammation in the 
pathogenesis of DPN. Other enriched canonical pathways involved chemotaxis, immune cell 
trafficking, and production of nitric oxide and reactive oxygen species (ROS), which are 
also indicative of altered inflammatory responses.29
KU-596 broadly reversed the diabetes-induced activation of inflammatory pathways (Figure 
7B). Numerous cytokines and transcriptional regulators that were predicted to be activated 
by diabetes showed an almost quantitative reversal by novologue therapy in WT mice 
(Supporting Table 3, Supporting Information). These data provide the first evidence that 
modulation of inflammatory pathways might contribute to the neuroprotective effects of 
KU-596.
Despite the difference between the gene sets affected in the Hsp70 KO and WT mice, 
inflammation was still among the top canonical pathways significantly enriched and 
increased in activity in the diabetic Hsp70 KO mice (Figure 7C). However, the increase in 
inflammatory pathways was not as robust in the diabetic Hsp70 KO mice. This may be 
related to a role of Hsp70 in the stimulation of pro-inflammatory cytokine production and 
recruitment of macrophages and monocytes.30,31 Unexpectedly, inflammatory pathways 
were also broadly downregulated in diabetic Hsp70 KO mice treated with KU-596 (Figure 
7D and Supporting Table 3, Supporting Information). Thus, KU-596 decreased the 
inflammatory response in diabetic sensory neurons through one or more Hsp70-independent 
pathways, but this was not sufficient to improve the sensory deficits (Figures 4B,D).
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Recent studies suggest that Hsp70 is actively released into the extracellular milieu to 
promote innate and adaptive immune responses under stress conditions32 and that the 
physiological function of Hsp70 largely depends on the location of the protein.33 Consistent 
with this premise, Hsp70.1-deficent mice were more resistant to developing autoimmune 
encephalomyelitis, suggesting the involvement of Hsp70.1 in promoting an effective myelin 
oligodendrocyte glycoprotein T cell response.34 Increased extracellular Hsp70 has been 
associated with inflammatory and oxidative stress conditions,35 whereas increased 
intracellular Hsp70 confers cellular protection through anti-inflammatory effects.36 In this 
regard, increased concentrations of extracellular Hsp70 and decreased concentrations of 
intracellular Hsp70 have been reported in type 2 diabetic patients.37 Conceivably, 
extracellular Hsp70 may mediate the activation of inflammatory pathways in WT diabetic 
sensory neurons, which may contribute to the weaker transcriptomic changes of these 
pathways in the diabetic Hsp70 KO mice.
Among the inflammation genes, CD163 is a macrophage and monocyte scavenger receptor 
that mediates endocytosis of haptoglobin-hemoglobin complexes. CD163 is a macrophage-
derived low-grade inflammation marker that indicates a level of macrophage activation.38 
Though macrophages have been detected in nerve after 8 weeks of diabetes,39 whether they 
are a cause or consequence of the developing DPN is unclear. However, a recent case-
control study involving a small number of type 2 diabetic patients indicated that an increase 
in soluble CD163 levels in cerebrospinal fluid and serum was associated with impaired large 
fiber function and incidence of DPN.40 In the current study, CD163 was increased ~3-fold in 
WT diabetic sensory neurons and decreased ~2-fold by KU-596 treatment (Supporting Table 
1, Supporting Information). CD163 was also upregulated 1.4-fold in diabetic Hsp70 KO 
neurons, but this did not quite reach statistical significance (q < 0.06). However, qPCR 
showed a significant increase in CD163 expression ((3.6 ± 1.6)-fold, Veh vs STZ; p < 0.05) 
in the diabetic Hsp70 KO mice, and this increase was unaffected by KU-596 when assessed 
by qPCR ((4.3 ± 0.7)-fold, Veh vs STZ + KU-596) or RNA Seq (1.7-fold, Veh vs STZ + 
KU-596). Therefore, Hsp70 does not necessarily have a role in increasing the expression of 
CD163 in diabetic macrophages, but the novologue may decrease this inflammatory marker 
in a Hsp70-dependent manner. Given the putative link that type 2 diabetic patients with 
neuropathy show a greater increase in serum CD163 levels than diabetic individuals without 
neuropathy, the ability of KU-596 therapy to decrease its expression may provide a 
biomarker for drug efficacy.40 However, since the mean duration of diabetes in this pool of 
type 2 diabetics was 13 years, it is not possible to determine whether CD163 may be a 
marker for diabetic damage or if early activation of macrophages may contribute to the large 
fiber impairment. Moreover, whether the relationship between serum CD163 levels and 
markers of neuropathy may extend to type 1 diabetic patients with DPN remains to be 
clarified.
Although inflammation is strongly associated with the development of DPN in mouse 
models of type 2 diabetes,24,41 an increase in inflammatory markers such as TNFα and 
IL-1β in DRG of type 1 diabetic rats has also been noted. Induction of Hsp70 following 
weekly exercise correlated with a decrease in these inflammatory mediators and an 
improvement in measures of painful neuropathy.42,43 Interestingly, inflammatory markers 
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such as neuropeptide Y (NPY) and NOX2 (NADPH oxidase 2 or Cybb, cytochrome b(245) 
subunit β) were increased at the protein or gene expression level in bone marrow of type 1 
diabetic rats. These inflammatory markers were decreased by treatment with an aldose 
reductase inhibitor plus lipoic acid, which correlated with an improvement in measures of a 
sensory neuropathy.44 These genes were similarly increased by diabetes in our study and 
decreased by KU-596. Thus, inflammation may be a contributing feature to both painful and 
insensate diabetic neuropathy that is amenable to chaperone modulation. However, a role of 
inflammation in contributing to DPN in murine models of type 1 diabetes needs to be 
cautiously assessed as it may be affected by genotypic variations in the C57Bl/6 strains that 
are used. For example, the primary genotypic variant between C57Bl/6J and C57Bl/6N 
strains is deletion of exons 7–12 for the gene encoding the mitochondrial enzyme 
nicotinamide nucleotide transhydrogenase (nnt gene) in C57Bl/6J mice. The absence of this 
gene differentially affects glucose homeostasis in response to a high fat diet compared with 
C57Bl/6N mice.45 Additionally, the loss of nnt promotes a redox imbalance in mitochondria 
that can increase susceptibility to oxidative stress and apoptosis.46 Thus, nnt deletion may 
impact the gene expression profile with this strain in diabetic and prediabetic peripheral 
neuropathies. Our current and past studies have used the C57Bl/6N as our wild-type line, 
which expresses a functional nnt gene. Examination of the RNA Seq alignments between the 
WT and Hsp70 KO mouse showed no differences in the detection of nnt exons and the 
FPKM values were essentially identical between the strains. Thus, it is unlikely that that 
activation of inflammatory or oxidative stress responses in our diabetic mice is confounded 
by this gene deletion.
Hsp70 Is Associated with a Decrease in Genes Linked to the Production of Oxidative 
Stress
Not unexpectedly, another over-represented biologic process in the diabetic WT (Figure 8A) 
and Hsp70 KO (Figure 8C) sensory neurons comprised genes involved in the production of 
ROS. However, KU-596 treatment was predicted to significantly normalize the expression 
of these genes only in the diabetic WT mice (Figure 8B), suggesting that the drug may 
reduce oxidative stress in a Hsp70-dependent manner. Oxidative stress is considered to be 
an essential pathogenic mechanism for DPN.47–49 Hyperglycemia changes multiple 
biochemical and metabolic pathways that can converge at the level of ROS production to 
contribute to the development and progression of DPN.50 For example, Cybb (NOX2), a 
superoxide generating enzyme that forms ROS,51 increased ~2-fold in diabetic WT sensory 
neurons and was reduced ~2-fold by KU-596 treatment. Thioredoxin interacting/inhibiting 
protein (Txnip) is induced by diabetes,52 and it promotes oxidative stress through interacting 
with thioredoxin and blocking its ROS scavenging activity.53 Txnip was upregulated ~2-fold 
in diabetic neurons and down-regulated about 1.4-fold by KU-596. Though diabetes 
significantly increased the expression of Txnip in the Hsp70 KO DRG by about 1.4-fold, 
this was unaffected by KU-596 treatment, which was validated by qPCR as well (data not 
shown). Therefore, limiting ROS production and reducing oxidative stress in the sensory 
neurons might represent an important Hsp70-dependent pathway through which KU-596 
exhibits efficacy on reversing sensory deficits of DPN. Though the exact mechanism 
through which Hsp70 modulates ROS production remains to be determined, its 
overexpression has been associated with protection against age-related oxidative stress.54 
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Mechanistically, this may be a rather direct effect on the neurons rather than by indirectly 
decreasing inflammation since we have shown that KU-32 increased the translation of 
MnSOD and decreased oxidative stress using in vitro cultures of hyperglycemically stressed 
rat embryonic sensory neurons.19
KU-596 and the Mitochondrial Transcriptome
KU-596 (Figure 3) and KU-3221 both reversed mtBE deficits in diabetic sensory neurons. 
Thus, one expectation was that transcriptome analysis would reveal gene clusters connecting 
to aspects of mitochondrial function. However, none of the genes involved in cellular 
bioenergetic activities were significantly altered in the STZ + Veh or STZ + KU-596 groups 
of WT mice. This observation suggests that the alterations in mtBE in the diabetic sensory 
neurons may not be due to transcriptome changes in genes involved in mitochondrial 
function. Because our prior proteomic study reported that diabetes decreased the expression 
of mitochondrial proteins,55 diabetes and KU-596 may exert their effects on mtBE at the 
protein level. Modulation of molecular chaperones may exert effects on mitochondrial 
function post-translationally through refolding of damaged proteins, by facilitating protein 
import into mitochondria, or by decreasing oxidative stress. In addition, it has been 
suggested that inflammatory signaling leads to changes in the phosphorylation state of 
mitochondrial proteins, which results in an inhibition of respiratory chain activity, a 
reduction of the mitochondrial membrane potential, and consequently a lack of energy 
production.56 In this regard, the effect of KU-596 to improve mtBE might be partially 
attributed to its effects in ameliorating inflammatory signaling in the sensory neurons.
Curiously, KU-596 decreased the transcription of several mitochondrial genes in diabetic 
Hsp70 KO sensory neurons even though only one these genes (ndufb2) was significantly 
increased in diabetic mice that did not receive the drug (Supporting Table 4, Supporting 
Information). This effect was not observed in diabetic WT mice or nondiabetic Hsp70 KO 
treated with the drug. Though mtBE was not measured in the diabetic Hsp70 KO mice 
treated with KU-596, the decrease in mRNA levels of these mitochondrial proteins was 
unlikely to result in changes in mitochondrial respiration since KU-32 did not decrease 
mtBE in sensory neurons isolated from diabetic Hsp70 KO mice.21 Although the underlying 
reason is unknown, this effect of KU-596 on mitochondrial transcripts might be associated 
with a role of Hsp90 in mitochondrial protein turnover. In the absence of Hsp70, the effects 
of KU-596 on transcriptome changes may be exerted through inhibiting Hsp90 activity. A 
previous in vitro study showed that Hsp90 inhibition led to post-translational accumulation 
of several mitochondrial oxidative phosphorylation complex subunits without corresponding 
changes in mRNA abundance.57 Thus, the decrease in transcription observed in our study 
might be an innate response to the accumulation of these mitochondrial proteins due to 
inhibition of Hsp90 over the 4 weeks of drug treatment. As an essential molecular chaperone 
that assures the correct folding and maturation of a number of cellular proteins, Hsp90 
inhibition leads to a global repression of protein synthesis and an increase in the degradation 
of its client proteins.58 This finding is consistent with our observation that KU-596 also 
decreased a subset of 25 ribosomal proteins only in diabetic Hsp70 KO sensory neurons. A 
recent proteomics study using human T cells revealed that Hsp90 inhibition resulted in the 
depletion of proteins involved in transcription and DNA damage response as well as a mild 
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but general decrease of ribosomal proteins and other components of the protein synthesis 
machinery.59 Considering these data, the differences in the gene sets affected by KU-596 in 
WT versus Hsp70 KO mice might be related to the distinct downstream pathways induced 
by drug treatment in the genotypes: whereas KU-596 exerts cytoprotective effects through 
Hsp70 in WT cells, the effects of KU-596 may be largely exerted through inhibiting the 
activity of Hsp90 in Hsp70 KO cells.
SUMMARY AND CONCLUSIONS
The current work extends our prior observations that modulating Hsp90 activity with small 
molecules that target the protein’s C-terminal domain may provide a novel translational 
approach toward treating insensate DPN. KU-596 represents the next generation of 
novobiocin-based molecules whose efficacy in reversing symptoms of DPN requires Hsp70 
and is linked to improving sensory neuron mtBE and decreasing inflammatory pathways. 
Though KU-596 decreased the activation of inflammatory pathways in diabetic Hsp70 KO 
mice, this was not sufficient to rescue the sensory deficits. Thus, the decrease in 
inflammatory markers in diabetic WT mice treated with KU-596 is likely parallel to the 
main mechanism for improving DPN, at least in the type 1 diabetes that is modeled in the 
current work. On the other hand, the decrease in genes linked to the production of ROS was 
more Hsp70-dependent, suggesting that this may underlie the improvement in mtBE and 
sensory function. Nonetheless, the decrease in inflammatory pathways may be a critical 




Streptozotocin (STZ), carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP), 
oligomycin, rotenone, antimycin A, Percoll, and poly(DL)ornithine were obtained from 
Sigma-Aldrich (St. Louis, MO). KU-596, N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-
methoxy-6,6-dimethyltetrahydro-2H–pyran-2-yl)oxy)-3′-fluoro-[1,1′-biphenyl]-2-yl)ethyl)-
acetamide, was synthesized, and structural purity (>95%) was verified as described 
previously.20
Animals
Male Swiss Webster mice were purchased from Harlan Laboratories (Indianapolis, IN). 
Male and female wild-type (WT) C57Bl/6 and Hsp70.1/70.3 double knockout (KO) mice on 
a C57Bl/ 6 background (Hsp70 KO) were obtained from in-house breeding colonies. The 
WT mice (C57Bl/6NHsd) were originally obtained from Harlan Laboratories, and the Hsp70 
KO mice were initially obtained from the Mutant Mouse Resource and Research Center. All 
animals were maintained on a 12-h light/dark cycle with ad libitum access to water and 7022 
NIH-07 rodent chow (5.2% fat). All animal procedures were performed in accordance with 
protocols approved by the Institutional Animal Care and Use Committee and in compliance 
with standards and regulations for the care and use of laboratory rodents set by the National 
Institutes of Health.
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Diabetes was induced in male Swiss Webster mice by an intraperitoneal injection of 100 
mg/kg STZ given on two consecutive days after 6 h of fasting. Fasting blood glucose (FBG, 
One Touch Ultra glucometer) was determined 1 week after the second injection following 6 
h of food withdrawal. Mice with FBG ≥ 290 mg/dL (16 mM) were deemed diabetic. FBG 
and glycated hemoglobin (HbA1c, A1c Now+) were also measured at study termination. 
KU-596 was administered after 8 weeks of diabetes via once per week intra-peritoneal 
injections of 2, 10, or 20 mg/kg in 0.1 M Captisol (β-cyclodextrin sulfobutylethers; CyDex 
Pharmaceuticals, Lenexa, KS). Of note, the vehicle–vehicle and diabetes–vehicle mice were 
part of a larger dose–response comparison study between KU-32 and KU-596. However, 
only the dose–response profile of KU-32 has been previously published.21
In the RNA Seq study, diabetes was induced in 8-week-old male and female WT or Hsp70 
KO mice as described above. After 12 weeks of diabetes, 20 mg/kg KU-596 in 0.1 M 
Captisol was given to the mice vial oral gavage (~0.2 mL) once per week for 4 weeks. Mice 
were randomly assigned to each of the treatments in both studies.
Psychosensory and Electrophysiologic Analyses
Mechanical sensitivity was assessed using a dynamic plantar aesthesiometer (Stoelting Inc.) 
fitted with a stiff monofilament that was applied to the plantar surface at an upward force of 
10 g for Swiss Webster mice or 8 g for C57Bl/6 and Hsp70 KO mice. Thermal sensitivity 
was assessed by paw withdrawal latency to a ramping, focal heat using a Hargreaves 
analgesiometer (Stoelting Inc.).21 Responses from each animal were measured four times on 
alternate feet and averaged. At the end point of a study, animals were anesthetized prior to 
measuring motor and sensory nerve conduction velocities (MNCV and SNCV) as previously 
described.60 Animals were then euthanized prior to tissue collection.
Mitochondrial Bioenergetics Assessment
Oxygen consumption rate (OCR) was assessed in intact lumbar DRG sensory neurons using 
the XF96 extracellular flux analyzer (Seahorse Biosciences, North Billerica, MA). Lumbar 
sensory neurons were dissected from two to three mice and pooled together, and the neurons 
were isolated as previously described.21 The cells were maintained overnight in Ham’s F10 
medium (6.1 mM glucose) containing 50 ng/mL nerve growth factor, 1 ng/mL neurotrophin 
3 and N2 supplement without insulin (Invitrogen, Carlsbad, CA). The following day, the 
medium was changed to unbuffered DMEM supplemented with 1 mM sodium pyruvate and 
5.5 mM D-glucose, and the cells were incubated at 37 °C for 1 h before being introduced to 
the XF96 analyzer. The initial readings provide a measure of the basal OCR before the 
addition of respiratory chain poisons.61 The addition of oligomycin (1 µg/mL), an ATP 
synthase inhibitor, leads to a decrease in OCR which represents the portion of basal OCR 
that is coupled to ATP synthesis. The residual OCR that persists after addition of oligomycin 
is from uncoupled respiration (proton leak). Next, maximal respiratory capacity (MRC) was 
assessed by adding 1 µM FCCP, a protonophore that dissipates the proton gradient across 
the inner mitochondrial membrane. Nonmitochondrial respiration was then assessed by co-
injection of 1 µM rotenone + 1 µM antimycin A. After the respiratory measures, the cells 
were harvested, and OCR values were normalized to the total protein content of each well. 
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Maximal respiratory capacity (MRC) and spare respiratory capacity (SRC) were quantified 
as described previously.61,62
Isolation of RNA
L4– L6 lumbar DRG from two animals were pooled together for the isolation of one total 
RNA sample. Each treatment group contained three to five biological replicates. Tissues 
were harvested, rapidly frozen in liquid nitrogen and stored at −80 °C. The tissue was 
ground in liquid nitrogen, and 900 µL of Trizol was added to each sample. RNA was 
isolated following the standard protocol of the Qiagen RNeasy Plus Universal Mini Kit 
(Qiagen, Venlo, CA). RNA quality and concentration was checked with the Agilent 2200 
Tape Station (Agilent Technologies, Santa Clara, CA) and Qubit fluorometric quantitation 
(Life Technologies, Carlsbad, CA), respectively. RNA with an integrity number (RIN) ≥ 7 
was used for RNA-Seq analysis or qRT-PCR analysis.
Illumina RNA-Seq
Total RNA (100 ng) was used to prepare cDNA libraries with the TruSeq stranded total 
RNA library prep kit (Illumina Inc., San Diego, CA). In general, poly(A)+ containing 
mRNA was purified with oligo-dT attached magnetic beads. Purified mRNA was then 
fragmented and primed with random hexamers, which were subsequently reverse transcribed 
into first strand cDNA using reverse transcriptase. The RNA templates were then removed 
from the single-strand cDNA and a replacement strand was synthesized to generate double-
strand cDNA. The double-strand cDNA was end-repaired and adenylated at the 3′ ends. For 
each sample, Illumina-specific adaptors that contain a unique 6 bp index sequence that 
identifies each sample were ligated to the 3′ adenine-tail of the fragments to permit the 
single read, multiplex sequencing of transcripts within each lane of the flow cell. cDNA 
products (~260 bp) were amplified and submitted to quality control with the Agilent 2200 
Tape Station. cDNA libraries prepared from the three to five biological replicates from each 
treatment group were then randomly assigned to two lanes of the flow cell for subsequent 
single-end sequencing with a read length of 100 bases using the Illumina HiSeq 2500 
System (Illumina Inc., San Diego, CA).
Bioinformatics Analysis of RNA-Seq Data
After the initial processing and demultiplexing steps with the Illumina Analysis Visual 
Controller software, the resulting FASTQ files were analyzed via the Galaxy Project web-
based portal63 (http://usegalaxy.org/) linked to the freely available Tuxedo Suite.64,65 
FASTQ files were quality checked using FASTQC and used ungroomed (Supporting Figure 
1, Supporting Information). The files were submitted to the Tophat module to align the short 
read sequences to the mouse genome (mm9). The reads for each biological replicate were 
mapped independently and submitted to Cufflinks, which assembled and annotated the 
transcripts of each sample. The resulting files for all treatments were merged with the 
reference genome using CuffMerge. The CuffMerge output and Tophat files were loaded 
into the CuffDiff module to quantify significant changes in transcript expression between 
groups.64,65 Gene level expression data were normalized to obtain fragments per kb per 
million aligned reads (FPKM), and the log 2-fold change between groups was calculated 
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based on the FPKM data. A t test was used to calculate the p-value for differential gene 
expression in the Cuffdiff module and the resulting p-values were adjusted by the 
Benjamini–Hochberg method to compute the false discovery rate.66 Genes with q-value 
≤0.05 were deemed differentially expressed and submitted to Ingenuity Pathway Analysis 
(http://www.ingenuity.com) to identify and model the gene networks.
Real-Time PCR
Quantitative real-time PCR (qRT-PCR) for select genes was performed using the Step One 
Plus real-time PCR system (Life Techonologies, Carlsbad, CA). Total RNA (150 ng) was 
reverse transcribed with oligo(dT)20 primers and Superscript III reverse transcriptase (Life 
Techonologies, Carlsbad, CA). One microliter of the cDNA was used as template in 
subsequent qRT-PCR reactions. The qRT-PCR reaction was performed with the Power 
SYBR Green master mix (Life Techonologies, Carlsbad, CA). The integrity of the PCR 
reaction was verified by melt curve analysis. All PCR primer sequences are listed in Table 5 
of the Supporting Information.
Statistical Analysis
Student’s t tests, one-way analysis of variance (ANOVA), and repeated measures one-way 
ANOVA were used for between-group comparisons. Post hoc analysis were conducted 
using Tukey’s test. All data are presented as mean ± SEM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
DPN diabetic peripheral neuropathy
DRG dorsal root ganglia
FBG fasting blood glucose
FCCP carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone
FPKM fragments per kb per million aligned reads
Hsp70 heat shock protein 70
Hsp90 heat shock protein 90
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MRC maximum respiratory capacity
mtBE mitochondrial bioenergetics
MNCV motor nerve conduction velocity
OCR oxygen consumption rate
RNA Seq RNA sequencing
SNCV sensory nerve conduction velocity
SRC spare respiratory capacity
STZ streptozotocin
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Structure of (A) KU-32 and (B) the novologue KU-596. The B-ring is fluorinated.
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Dose response of KU-596 in reversing mechanical (A) and thermal (B) hypoalgesia. (C) 
KU-596 attenuated deficits in motor and sensory nerve conduction velocity. *p < 0.05 vs 
Veh+Veh; ^p < 0.05 vs STZ + Veh; #p < 0.05 vs time-matched STZ + 2 mg/kg KU-596.
Ma et al. Page 19














(A) KU-596 improved MRC in the sensory neurons of diabetic mice in a dose-dependent 
manner. (B) Spare respiratory capacity (SRC) was quantified and expressed as percent of the 
control group (Veh + Veh). *p < 0.05 vs Veh + Veh; ^p < 0.05 vs STZ + Veh; #p < 0.05 vs 
STZ + 2 mg/kg KU-596.
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KU-596 reverses sensory deficits in diabetic mice in an Hsp70-dependent manner. Diabetic 
WT (A,C) and Hsp70 KO (B,D) mice showed little difference in the temporal onset or 
magnitude of the sensory hypoalgesia. KU-596 treatment was initiated after 12 weeks of 
diabetes, and mechanical (A) and thermal (C) hypoalgesia were partially reversed over 4 
weeks in C57Bl/6 mice. In contrast, drug treatment did not reverse either the mechanical (B) 
or thermal (D) hypoalgesia in the Hsp70 KO mice. *p < 0.05 vs Veh + Veh; ^p < 0.05 vs 
time-matched STZ + Veh.
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KU-596 therapy normalized the expression of numerous genes in a Hsp70 independent 
manner. The log2 fold change of genes that were detected in diabetic WT (A) and Hsp70 KO 
(B) mice in the absence (abscissa) and presence (ordinate) of KU-596 were plotted. Genes in 
red were altered in both the diabetic WT and Hsp70 KO mice.
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qRT-PCR validation of RNA-Seq data in C57Bl/6 mice. (A) Total RNA was prepared for 
mRNA quantification by standard qRT-PCR. Tubulin was used as the internal control. The 
data were expressed as fold change versus nondiabetic mice for each gene. *p < 0.05 vs Veh 
+ Veh; ^p < 0.05 vs STZ + Veh; n = 3. (B) Fold change versus nondiabetic mice using the 
normalized FPKM values from RNA-Seq
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Significantly altered biologic processes in WT (A, B) and Hsp70 KO mice (C, D). In both 
genotypes, diabetes activated inflammatory responses (A, C), and these were decreased by 
novologue treatment (B, D). The size of each box represents the negative log of the p-value 
of the genes associated with each biologic process, indicating enrichment. The color of each 
box indicates the activation z-scores; ≥2 (orange, activated) or ≤ −2 (blue, inhibited), gray, 
no effect.
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Genes involved in ROS production were increased in diabetic WT (A, B) and Hsp70 KO 
mice (C). WT Veh vs STZ + Veh (A) and STZ vs STZ + KU-596 (B). Hsp70 KO Veh vs 
STZ (C). Novologue therapy was only predicted to decrease this biologic process in diabetic 
WT mice. Red indicates upregulation of the molecules, and green indicates downregulation. 
Greater node color intensity corresponds to a higher level of change in expression. Edge 
color represent the predicted effects on the production of ROS: orange, activation; blue, 
inhibition; yellow, inconsistent with the activation state of the downstream molecule; gray, 
an effect is not predicted.
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Table 1
Weight, FBG, and HbA1c of Swiss Webster Mice
treatmenta weight, g FBG, mg/dL HbA1c, % (mmol/mol)b n
Veh + Veh 35.6 ± 2.4 153 ± 42 5.2 ± 0.1 (33.3 ± 1.1) 6
STZ + Veh 27.9 ± 2.2c 596 ± 7c 13.0 ± 0c,d (118.6 ± 0) 5
STZ + 2 mg/kg KU-596 30.4 ± 2.5c 554 ± 113c 12.6 ± 0.6c (114.2 ± 6.6) 6
STZ + 10 mg/kg KU-596 30.6 ± 2.1c 525 ± 128c 11.9 ± 1.3c (106.6 ± 14.3) 7
STZ + 20 mg/kg KU-596 29.0 ± 2.0c 600 ± 0c,d 12.9 ± 0.1c (117.5 ± 1.1) 7
Veh + 20 mg/kg KU-596 34.1 ± 1.4 128 ± 10 5.1 ± 0.2 (32.2 ± 0.2) 7
a
Veh, vehicle; STZ, streptozotocin.
b
mmol of HbA1c/mol of hemoglobin.
c
p < 0.05 versus Veh + Veh. Veh for STZ was 0.1 M sodium citrate in PBS, pH 4.5; Veh for KU-596 was 0.1 M Captisol in water.
d
Maximal reading.
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